Jasper Therapeutics (JSPR) Change in Receivables (2023)
Jasper Therapeutics (JSPR) posted Change in Receivables of -$663000.0 for Q1 2023.
Powered by 
Analysis
Jasper Therapeutics (JSPR) Change in Receivables (2023) Analysis & Trends
Jasper Therapeutics has reported Change in Receivables for 1 years, with the latest figure at -$663000.0 in Q1 2023.
- On a quarterly basis, Change in Receivables changed N/A year-over-year to -$663000.0 in Q1 2023; TTM through Dec 2023 was -$663000.0, a N/A change from a year earlier, with the FY2023 full-year figure at -$663000.0, down 200.0% from the prior year.
- Change in Receivables was -$663000.0 for Q1 2023 at Jasper Therapeutics.
- The five-year high for Change in Receivables was -$663000.0 in Q1 2023, with the low at -$663000.0 in Q1 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 1.09 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 333.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 140.20 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 838.50 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -53.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 31.60 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 269.40 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Jasper Therapeutics | 20.11 Mn | 20.11 Mn | - | - |